Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Anita Russi"'
Autor:
Michele De Bonis, Ottavio Alfieri, Fabiana Blunda, Cosmo Godino, Claudia Rubino, Alberto Margonato, Anita Russi, Alberto Zangrillo, Michela Cera, Davide Margonato, Paolo Della Bella, Alberto Cappelletti, Anna Salerno, Matteo Montorfano, Paolo Mattiello, Massimo Filippi, Patrizio Mazzone, Francesca Bodega, Alessandro Castiglioni, Francesco Melillo, Moreno Tresoldi, INSigHT registry investigators
Publikováno v:
Minerva Medica. 114
BACKGROUND Limited real-world data are available regarding the comparison about safety and efficacy of DOACs prescription in very elderly patients (≥85 years) with non-valvular atrial fibrillation (NVAF). Concern about the risk of bleeding with ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df8d45db1bd7165015cb75e36ee55335
https://doi.org/10.23736/s0026-4806.21.07432-2
https://doi.org/10.23736/s0026-4806.21.07432-2
Autor:
Alberto Cappelletti, Margonato Alberto, Giulio Leo, Patrizio Mazzone, Matteo Montorfano, Michele De Bonis, Ottavio Alfieri, Fabiana Blunda, Paolo Della Bella, Paolo Mattiello, Michela Cera, INSigHT registry investigators, Massimo Filippi, Claudia Rubino, Francesco Melillo, Moreno Tresoldi, Alessandro Castiglioni, Cosmo Godino, Anna Salerno, Anita Russi, Francesca Bodega, Alberto Zangrillo
Publikováno v:
European journal of clinical investigationREFERENCES. 52(1)
Background: Limited clinical data exist describing the use of direct oral anticoagulants (DOACs) in patient with extreme body weight. Thus, the International Society of Thrombosis and Haemostasis (ISTH) recommends avoiding DOACs in patients with weig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::660ba40fad40bf2df748cf491fdc9f42
https://pubmed.ncbi.nlm.nih.gov/35506326
https://pubmed.ncbi.nlm.nih.gov/35506326
Autor:
Carlo Andrea Pivato, Claudia Rubino, Cosmo Godino, Alberto Margonato, Michela Cera, Anita Russi
Publikováno v:
The American Journal of Cardiology. 129:122-124
What is the optimal antithrombotic therapy in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) remains one of the most doubtful and demanding topics in cardiology. As of today, there are no trial powered to p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ee5d0b214068bd8a7beb46207333743
https://doi.org/10.1016/j.amjcard.2020.05.012
https://doi.org/10.1016/j.amjcard.2020.05.012